Evommune (EVMN) stock: insider trades, news & valuation
Strong buyingShare price and insider trades
Evommune insider trading at a glance (Oct 9, 2026): in the past 12 months, 6 insiders bought $70.2M and 6 sold $2.3M of EVMN stock on the open market, including a cluster buy that began Nov 7, 2025.
Get emailed when insiders cluster-buy stocks like EVMN
Free alerts the day a new cluster buy is filed, plus the Monday report of the week's biggest insider trades.
Free · unsubscribe anytime · not investment advice · see a sample issue
EVMN insider buying and selling by quarter
Open-market purchases (green, above the line) and sales (red, below), by trade date.
| Quarter | Bought | Purchases | Sold | Sales |
|---|---|---|---|---|
| Q4 2026 | — | 0 | — | 0 |
| Q3 2026 | $146K | 2 | — | 0 |
| Q2 2026 | — | 0 | $2.3M | 9 |
| Q1 2026 | — | 0 | — | 0 |
| Q4 2025 | $70.0M | 5 | — | 0 |
Valuation, profit and volume
Summary
Over the past 12 months, 6 Evommune, Inc. insiders reported open-market purchases totaling $70.2M, while 6 insiders reported sales totaling $2.3M. The most recent cluster buy began on Nov 7, 2025, when 3 insiders bought a combined $70.0M. Among insiders with enough purchase history to measure, Ra Capital Management, L.P. (Director) has the highest Insider Score at 92. 9 of 9 recorded sales were made under pre-scheduled Rule 10b5-1 trading plans, which are usually less informative than discretionary sales.
Insider transactions
Open-market purchases and sales.
| Filed | Insider | Type | Shares | Price | Value | Since | Score |
|---|---|---|---|---|---|---|---|
| Jul 10SEC | Kyle CarverCFO | Buy | 1,00060,335 held (+2%) | $13.26 | $13K | -52.9% | — |
| Jul 8SEC | Arthur S KirschDirector | Buy | 10,000new position | $13.30 | $133K | -53.0% | — |
| Jun 24SEC | Janice Suzann DrewChief Of Dev. Operations | Sell Plan | 20,00067,794 held (−23%) | $22.63 | $453K | -72.4% | — |
| Jun 24SEC | Luis C. PenaCEO, President | Sell Plan | 7,438630,458 held (−1%) | $22.71 | $169K | -72.5% | — |
| Jun 24SEC | Jeegar Pravinkumar PatelChief Scientific Officer | Sell Plan | 1,48846,403 held (−3%) | $22.50 | $33K | -72.2% | — |
| Jun 3SEC | Luis C. PenaCEO, President | Sell Plan | 16,787637,896 held (−3%) | $22.74 | $382K | -72.5% | — |
| Jun 3SEC | Jeegar Pravinkumar PatelChief Scientific Officer | Sell Plan | 16,68746,403 held (−26%) | $22.74 | $379K | -72.5% | — |
| Jun 3SEC | David E CohenDirector | Sell Plan | 5,45618,209 held (−23%) | $20.21 | $110K | -69.1% | — |
| Jun 3SEC | David E CohenDirector | Sell Plan | 60017,609 held (−3%) | $21.38 | $13K | -70.8% | — |
| Jun 1SEC | Kyle CarverCFO | Sell Plan | 18,17559,335 held (−23%) | $22.84 | $415K | -72.6% | — |
| Jun 1SEC | Gregory S. MossChief Business & Legal Officer | Sell Plan | 14,22360,835 held (−19%) | $22.83 | $325K | -72.6% | — |
| Dec 22SEC | Robert Lorne HopfnerDirector | Buy | 1,0004,026 held (+33%) | $17.35 | $17K | -64.0% | — |
| Nov 12SEC | Weegen Felice Isabel Verduyn-vanDirector | Buy | 1,562,5004,929,633 held (+46%) | $16.00 | $25.0M | -60.9% | — |
| Nov 12SEC | 7 Cooperative Ua Lsp10% Owner | Buy | 1,562,5004,929,633 held (+46%) | $16.00 | $25.0M | -60.9% | — |
| Nov 12SEC | Ra Capital Management, L.P.Director | Buy | 1,157,0962,674,425 held (+76%) | $16.00 | $18.5M | -60.9% | 92 |
| Nov 12SEC | Ra Capital Management, L.P.Director | Buy | 92,904784,345 held (+13%) | $16.00 | $1.5M | -60.9% | 92 |
Insiders at Evommune, Inc.
| Insider | Bought | Sold | Last filing | Score |
|---|---|---|---|---|
| Weegen Felice Isabel Verduyn-vanDirector | $25.0M | — | Nov 12, 2025 | — |
| 7 Cooperative Ua Lsp10% Owner | $25.0M | — | Nov 12, 2025 | — |
| Ra Capital Management, L.P.Director | $20.0M | — | Nov 12, 2025 | 92 |
| Luis C. PenaCEO, President | — | $551K | Jun 24, 2026 | — |
| Kyle CarverCFO | $13K | $415K | Jul 10, 2026 | — |
| Janice Suzann DrewChief Of Dev. Operations | — | $453K | Jun 24, 2026 | — |
| Jeegar Pravinkumar PatelChief Scientific Officer | — | $413K | Jun 24, 2026 | — |
| Arthur S KirschDirector | $133K | — | Jul 8, 2026 | — |
| Gregory S. MossChief Business & Legal Officer | — | $325K | Jun 1, 2026 | — |
| David E CohenDirector | — | $123K | Jun 3, 2026 | — |
| Robert Lorne HopfnerDirector | $17K | — | Dec 22, 2025 | — |
EVMN stock: common questions
Are Evommune, Inc. insiders buying EVMN stock?
In the past 12 months, 6 insiders reported open-market purchases of EVMN worth $70.2M. The latest was CFO Kyle Carver bought $13K of EVMN at $13.26 — first open-market purchase in our records.
Are Evommune, Inc. insiders selling EVMN stock?
6 insiders reported sales worth $2.3M over the same period.
Where does this data come from?
Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.
What is EVMN's 52-week range?
Over the past year EVMN has traded between $6.22 and $31.57. It last closed at $6.25 on Oct 9, 2026.